Teladoc Health Appoints Cisco CEO Chuck Robbins to Board

TL;DR

TDOC adds Cisco CEO Chuck Robbins to its board, effective immediately.

AI Summary

Teladoc Health, Inc. announced on April 8, 2024, the appointment of Charles R. "Chuck" Robbins as a new Class II director, effective immediately. Robbins, the Chair and CEO of Cisco Systems, Inc., will serve on the Nominating and Corporate Governance Committee. This appointment follows the departure of two Class II directors, who did not stand for re-election.

Why It Matters

The addition of a high-profile executive like Chuck Robbins to Teladoc's board could signal strategic direction or bring valuable industry connections and oversight.

Risk Assessment

Risk Level: low — This filing is a routine corporate governance update regarding board appointments and does not involve significant financial or operational changes.

Key Players & Entities

• Teladoc Health, Inc. (company) — Registrant
• Charles R. "Chuck" Robbins (person) — Newly appointed Class II director
• Cisco Systems, Inc. (company) — Employer of new director
• Nominating and Corporate Governance Committee (company) — Committee Robbins will join

FAQ

From the Filing

0001477449-24-000094.txt : 20240412 0001477449-24-000094.hdr.sgml : 20240412 20240412160510 ACCESSION NUMBER: 0001477449-24-000094 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240408 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240412 DATE AS OF CHANGE: 20240412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 24841433 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240408.htm 8-K tdoc-20240408 FALSE 0001477449 0001477449 2024-04-08 2024-04-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 8, 2024, Mr. Richard J. Napolitano, Chief Accounting Officer (Principal Accounting Officer) of Teladoc Health, Inc. (the “Company”) informed the Company of his decision to resign, effective May 3, 2024, to pursue another career opportunity. Mr. Napolitano’s decision is due to personal reasons and is not a result of any disagreement with the Company on any